Best Grants for HIV / AIDS in Vermont

Vermont LGBTQ+ organizations and projects supporting HIV/AIDS prevention, harm reduction, and community health can seek grants for general support, specific projects, emergent needs, and queer event sponsorship. Vermont Community Foundation’s Samara Fund prioritizes queer- and trans-led, BIPOC- and trans-centered work, smaller-budget and long-term efforts, with awards up to US $5,000.

Organizations planning research on substance use, HIV prevention, or HIV eradication in the U.S., including Vermont, can apply for pilot and feasibility study funding through the National Institutes of Health. Grants from NIH help develop and test interventions, assess feasibility and acceptability, and build measures and methods for future large-scale trials with engaged community stakeholders.

Early-career HIV researchers working on chronic conditions, coinfections, and comorbidities can access funding through the National Institutes of Health for pioneering prevention and treatment studies, including in Vermont. Grants from National Institutes of Health help advance transformative HIV 3C research, especially focused on pediatric and maternal populations and innovative, cross-disciplinary approaches.

Vermont HIV/AIDS research institutions and investigators studying HIV immunotherapies and central nervous system (CNS) outcomes can access funding through the National Institutes of Health, with awards up to US $2,000,000. This upcoming R21/R33 opportunity supports biphasic projects evaluating CNS HIV persistence, neurotoxicity, neuroinflammation, and mechanisms, benefits, and risks of HIV immunotherapies across anatomical compartments.

Clinical research institutions conducting HIV and HIV-related clinical trials can apply for funding to operate Clinical Trials Units in Vermont and other eligible locations. Grants from US Dept. of Health & Human Services: National Institutes of Health support CTUs that provide scientific expertise, manage domestic and/or international clinical research sites, and run multiple randomized and implementation studies to help end the HIV epidemic.

Vermont research institutions and clinical trial organizations focused on HIV and HIV-associated diseases can access funding through the National Institutes of Health to serve as Statistical and Data Management Centers. These SDMCs design and coordinate HIV clinical trials, manage and analyze clinical and laboratory data, ensure data quality and regulatory compliance, and support innovative statistical methods across national HIV clinical trials networks.

Research institutions and clinical trial organizations working on HIV/AIDS prevention and treatment can apply for NIH funding to serve as Laboratory Centers within national HIV clinical trials networks, including work impacting Vermont. Awards support laboratory infrastructure, testing, data systems, and assay development to ensure high-quality, regulatory-compliant testing for HIV and HIV-related disease trials.

Research institutions focused on HIV/AIDS clinical trials and implementation science can apply to lead a Clinical Trials Network Leadership and Operations Center, guiding prevention, treatment, and cure-focused studies in the U.S., including Vermont. Focused on HIV/AIDS, the National Institutes of Health invites applicants to shape agendas in therapeutics, biomedical prevention, and immune-based strategies.

Research institutions conducting substance use, addiction, and HIV studies in Vermont and nationwide can apply for core center funding to build a transformative research hub. Focused on advancing addiction and HIV science, the National Institutes of Health supports centers that integrate existing projects, share resources, foster collaborations, and develop early-career investigators.

Research institutions and labs conducting HIV/AIDS studies in the U.S. and territories, including Vermont, can seek US $212,004 - US $2,725,311 to develop and manage specific pathogen free in vivo models and human new approach methodologies. US Dept. of Health & Human Services: National Institutes of Health supports NAMs triage services, human in vitro testing, and high-quality SPF colony resources.

Research institutions and centers conducting HIV/AIDS and mental health research in Vermont and other eligible U.S. locations can seek funding to establish or expand AIDS Research Centers. Grants from US Dept. of Health & Human Services: National Institutes of Health support interdisciplinary basic, clinical, behavioral, and implementation science projects that foster collaboration, innovation, and dissemination of HIV/AIDS research findings.

The Ryan White HIV/AIDS Program (RWHAP) Integrated HIV/AIDS Planning Resource Allocation Cooperative Agreement aims to enhance the effectiveness of HIV prevention and care planning for RWHAP Parts A and B recipients. Through the provision of training, tools, and technical assistance, this initiative seeks to optimize resource allocation and strengthen the overall system of HIV care and treatment, ultimately improving health outcomes for those affected by HIV.

The AIDS Drug Assistance Program (ADAP) Emergency Relief Funds aim to provide essential funding to states and territories. This initiative focuses on preventing, reducing, or eliminating waiting lists for ADAP services, ensuring timely access to necessary medications and support for individuals living with HIV/AIDS. This program addresses critical funding shortfalls, enhancing the healthcare infrastructure and improving health outcomes in affected communities.

The Ryan White HIV/AIDS Program Part C Capacity Development Program aims to enhance the capabilities of community-based organizations, focusing on improving health outcomes and decreasing HIV transmission. This initiative supports individuals who have not yet accessed regular HIV care, emphasizing innovative care solutions and infrastructure development to address these critical needs.

The HIV Care Grant Program, funded by the US HHS: Health Resources & Services Administration (HRSA), aims to enhance access to high-quality HIV care and treatment for low-income individuals. This initiative supports states and territories in developing comprehensive systems to address the needs of those living with HIV. By providing essential resources, the program seeks to improve health outcomes and ensure that vulnerable populations receive the necessary support and services.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The HIV Care Grant Program aims to enhance access to comprehensive, high-quality HIV care and treatment for low-income individuals in Pacific Island territories. Funded by the US HHS: Health Resources & Services Administration (HRSA), this initiative supports states and territories in developing effective systems of care, ensuring that those affected by HIV receive the necessary treatment and support to improve health outcomes.

This funding opportunity aims to enhance a web-based ordering portal for distributing 1.5 million HIV and STI self-tests to high-burden communities. By optimizing access to these self-tests, the initiative seeks to raise awareness, prevent new infections, and improve the health outcomes of users, thereby contributing to better overall public health and wellbeing.

This project aims to enhance health outcomes for women living with HIV in the South by integrating HIV care with comprehensive women's health services through coordinated Clinic and Community Collaboratives. By funding organizations to implement targeted strategies such as culturally responsive services and learning collaboratives, the initiative seeks to improve access to essential health services, increase the number of women initiating rapid ART, and foster sustainable healthcare models that address the unique needs of this population.

The Ryan White HIV/AIDS Program Part D provides supplemental funding aimed at enhancing the infrastructure and capacity of organizations to deliver high-quality, family-centered HIV care services. This initiative focuses on two key areas: HIV Care Innovation and Infrastructure Development, ensuring improved access to essential services for women, infants, children, and youth affected by HIV.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

Gilead Sciences

At Gilead, we are relentlessly committed to advancing transformative therapies for the most serious diseases, delivering an exponentially positive impact on health.

For more than three decades, we have combined scientific rigor with a deep sense of purpose to improve health outcomes and reimagine care. Our work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation, where unmet medical needs remain greatest.

From individual patients to whole populations, we’re committed to delivering healthier futures for people and communities worldwide.

Our Mission: To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

HIV Prevention NOVA 2026

Program Description

Gilead Sciences invites research proposals that advance the evidence base for innovative and scalable models of delivery for long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the United States.

This Topic of Interest (TOI) is focused on care delivery models implemented in non-traditional settings, defined as clinical and non-clinical environments where PrEP services are not routinely provided. Emphasis is placed on approaches that reflect real-life practice and address gaps in current PrEP delivery infrastructure.

Persistent inequities in PrEP uptake in the U.S. suggest that expanding availability within traditional clinical settings alone is unlikely to reach all populations with unmet PrEP need.1,2 Rigorous implementation studies in non-traditional settings where PrEP services are not routinely provided are needed to evaluate whether these models can reduce access barriers and improve equitable reach among individuals who may benefit from PrEP.2,3,4

The goal of this TOI is to generate practical, decision-relevant evidence that informs how LA PrEP can be implemented, scaled, and sustained in real-life U.S. settings.

About Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Who we are and our impact

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

HIV, AIDS, and prevention

Help with healthcare costs for HIV, AIDS, and prevention

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

About the disease

HIV, also known as human immunodeficiency virus or acquired immunodeficiency syndrome, is a virus that attacks the immune system. When left untreated, it can develop into AIDS. HIV is a chronic disease that affects the immune system.

The SCORCH Program: Phase 2 aims to enhance the understanding of single cell biology in the context of HIV and Substance Use Disorder (SUD). Building on previous research, this initiative will explore new single cell approaches to investigate the interactions between SUD and HIV progression at various biological levels. By leveraging advanced techniques, the program seeks to identify candidate mechanisms and potential therapeutic targets, ultimately contributing to innovative solutions for SUDs and HIV-related challenges.

Bristol Myers Squibb is dedicated to enhancing healthcare and advancing scientific knowledge through its Corporate Giving program. By supporting various organizations, BMS aims to improve health equity and access to essential medicines for underserved populations. Their focus includes charitable donations, medical education, and community support initiatives. This commitment reflects BMS's goal to make a positive impact on patients' lives and foster strong communities where their employees work and live.

The Elizabeth Taylor AIDS Foundation (ETAF) provides grants focused on HIV/AIDS care, advocacy, and education. Grants are awarded annually based on a review process, emphasizing projects that align with Ms. Taylor’s vision. Eligible organizations must have at least three years of experience in HIV/AIDS programs and can apply only once per year. ETAF prioritizes funding for direct care and prevention initiatives, while restricting support for multi-year proposals and non-HIV specific projects.

The Gamma Mu Foundation, established in 1988, aims to support the LGBT community in rural and underserved areas through various grants. Initially focused on HIV/AIDS projects, it now funds scholarships and services for diverse LGBT subpopulations. With over $2 million awarded, the Foundation prioritizes initiatives that enhance community support, public education, and health programs. It emphasizes projects that build organizational capacity and provide essential services where resources are limited, ensuring ongoing support for vital health and social services.